A Asia-Pacific Asparaginase Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Escherichia coli, Erwinia chrysanthemi, Pegylated, and Others)

Asia-Pacific Asparaginase Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Escherichia coli, Erwinia chrysanthemi, Pegylated, and Others), Application (Therapeutic, Food Processing, and Others), and End-use Industry (Healthcare and Food Manufacturing) 

The APAC asparaginase market is expected to grow from US$ 132.43 million in 2022 to US$ 341.39 million by 2028; it is estimated to grow at a CAGR of 17.1% from 2022 to 2028.

Increase in Pharmaceutical R&D Activities and Investment by Market Players

The pharmaceutical industry is developing at a significant rate, and developed countries are investing heavily in the development of novel treatments for various diseases. The government-supported research funding in the industry and a surge in R&D activities for developing asparaginase with high compatibility and reduced side effects are expected to contribute to the asparaginase market growth. In addition, market players are collaborating on the production of asparaginase, which is being used as an active pharmaceutical ingredient in the pharmaceutical industry. Governments of various countries and asparaginase producers are investing heavily in the R&D of asparaginase, which is further expected to contribute to the market growth in the coming years. Furthermore, the rising need for better stability in the pharmaceutical industry to ensure efficient storage and transportation of drugs has also increased the R&D activities in the industry. Thus, all the factors mentioned above are expected to drive the asparaginase market growth over the forecast period.

Market Overview



The APAC asparaginase market is segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC. Further, China dominated the market in 2022. The growth of the market is primarily attributed to the growing pharmaceutical market, increasing developments by the market players, and favorable regulatory policies. The growing population of China and the rising prevalence of cancer are majorly driving the demand for cancer treatment drugs, such as asparaginase, in the country, making it a prime market in the region. As per the WHO report, in 2020, there were ~4,568,754 new cases of cancer and 3,002,899 deaths due to cancer in China. According to the Global Burden Disease (GBD) 2017 report, an estimated 141,317 new cases and 60,010 deaths of leukemia occurred in China, accounting for 27.3% of 518,485 new cases and 17.3% of 347,583 deaths worldwide, respectively. JINLAN Pharm-Drugs Technology Co., Ltd.; Jiwan Pharmaceutical Technology Co., Ltd; and Changzhou Qianhong are a few of the major Chinese market players that are producing and supplying asparaginase to many countries for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. Thus, a huge cancer patient population and developments in treatment for the disease by the market players are expected to propel the demand for asparaginase in the country.

APAC Asparaginase Market Revenue and Forecast to 2028 (US$ Million)

APAC Asparaginase Market Segmentation

The APAC asparaginase market is segmented based on type, application, end-use industry, and country.

Based on type, the APAC asparaginase market is segmented into escherichia coli, erwinia chrysanthemi, pegylated, and others. The escherichia coli segment held the largest market share in 2022. Based on application, the APAC asparaginase market is segmented into therapeutic, food processing, and others. The therapeutic segment held the largest market share in 2022. The therapeutic segment is further classified into acute lymphoblastic leukemia, lymphoblastic lymphoma, and others. Based on end-use industry, the APAC asparaginase market is bifurcated into healthcare and food manufacturing. The healthcare segment held the larger market share in 2022. Based on country, the APAC asparaginase market has been categorized into China, Japan, India, Australia, South Korea, and rest of APAC. Our regional analysis states that China dominated the market in 2022. Biovendor, LLC; Changzhou Qianhong Biopharma Co Ltd; Creative Enzymes; Jazz Pharmaceuticals, Inc.; medac GMBH; Servier Pharmaceuticals LLC; Taj Pharmaceuticals Limited; and United Biotech (P) Limited are the leading companies operating in the APAC asparaginase market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the APAC asparaginase market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the APAC asparaginase market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth APAC market trends and outlook coupled with the factors driving the asparaginase market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution